K
KisoJi Biotechnology
AI-powered therapeutic antibody discovery for oncology
About KisoJi Biotechnology
KisoJi Biotechnology is a privately-held Canadian company developing therapeutic antibodies for oncology, cardiometabolic disease, and immunology. Founded in 2009 by David S. Young, M.D., the company's mission is to improve outcomes in these fields through multi-specific antibodies. Young, who serves as CEO and CSO, previously founded ARIUS Research Inc., a therapeutic cancer antibody company acquired by Roche in 2008.
The company's business model revolves around its proprietary, in-house developed antibody discovery platform, which leverages artificial intelligence. This platform integrates several core technologies: KisoMouse®, a transgenic mouse platform for generating single-domain antibodies; KisoSeek™, an AI-driven tool for structural antibody screening and paratope mapping; and KisoBody™, a platform for creating multi-specific antibodies. The company claims to have created the world's largest single-domain antibody database, with over 25 million validated antibodies, which powers its AI platform. KisoJi's approach aims to visualize the complete immune response to identify antibodies with desired properties more efficiently than traditional methods.
KisoJi's lead product candidate is KJ-103, a 'naked' anti-TROP2 antibody for treating solid tumors. Unlike antibody-drug conjugates (ADCs), KJ-103 does not have a toxic payload and instead recruits the patient's own immune cells to attack cancer cells, potentially offering a safer treatment profile. In October 2024, KisoJi announced a partnership with Cancer Research UK to advance KJ-103 into a first-in-human Phase 1/2a clinical trial. To fund this clinical advancement and further develop its platform, the company raised $41 million USD in a Series B equity financing round in late 2024, led by Investissement Québec and Lumira Ventures.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2024 | $30M | $120M | Remiges Ventures · Fonds de solidarité FTQ · Invest Quebec · Lumira Ventures | ↗ |
| SERIES AEquity / VC | Jun 2018 | — | — | Remiges Ventures · Lumira Ventures · Fonds de solidarité FTQ | — |
Growth signals
Latest recorded traffic for KisoJi Biotechnology is 4.4K monthly website visits, up 537.7% over the last three months. KisoJi Biotechnology's team declined 66.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
KisoJi Biotechnology in the Montreal ecosystem
The KisoJi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Lumira Ventures
Accel-Rx Health Sciences Accelerator
Ccrm
Business Development Bank of Canada
Fonds de solidarité FTQ
Remiges Ventures
Invest Quebec
AdMare BioInnovations
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about KisoJi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KisoJi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





